HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer[Biotin], His & Avi, Human
| $510.00 | |
| Z06465-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $510.00 | |
| Z06465-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 50.50 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. |
| Synonyms | HPV16; E7; MHC |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.